Author:
Zhao Yaru,Liu Huihui,Zhan Qi,Jin Hao,Wang Yiqiang,Wang Hui,Huang Biao,Huang Fang,Jia Xiaoyuan,Wang Yigang,Wang Xiaoyan
Abstract
AbstractLHPP has been shown to be a new tumor suppressor, and has a tendency to be under-expressed in a variety of cancers. Oncolytic virotheray is a promising therapeutics for lung cancer in recent decade years. Here we successfully constructed a new recombinant oncolytic adenovirus GD55-LHPP and investigated the effect of GD55-LHPP on the growth of lung cancer cells in vitro and in vivo. The results showed that LHPP had lower expression in either lung cancer cells or clinical lung cancer tissues compared with normal cells or tissues, and GD55-LHPP effectively mediated LHPP expression in lung cancer cells. GD55-LHPP could effectively inhibit the proliferation of lung cancer cell lines and rarely affected normal cell growth. Mechanically, the oncolytic adenovirus GD55-LHPP was able to induce stronger apoptosis of lung cancer cells compared with GD55 through the activation of caspase signal pathway. Notably, GD55-LHPP also activated autophagy-related signal pathway. Further, GD55-LHPP efficiently inhibited tumor growth in lung cancer xenograft in mice and prolonged animal survival rate compared with the control GD55 or PBS. In conclusion, the novel construct GD55-LHPP provides a valuable strategy for lung cancer-targeted therapy and develop the role of tumor suppress gene LHPP in lung cancer gene therapy.
Funder
the Public Welfare Technology Project of Zhejiang Province
Zhejiang Medical Technology Plan Project
Hangzhou Science and Technology Bureau
Hangzhou Medical Health Science and Technology Project
the Applied Research and Cultivation Program of Jiangxi Province
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Siegel, R. L. et al. Cancer statistics, 2023. CA Cancer J Clin. 73(1), 17–48 (2023).
2. Bade, B. C. & Dela Cruz, C. S. Lung cancer 2020: Epidemiology, etiology, and prevention. Clin. Chest Med. 41(1), 1–24 (2020).
3. DePeaux, K. & Delgoffe, G. M. Integrating innate and adaptive immunity in oncolytic virus therapy. Trends Cancer S2405–8033(23), 00196–00206 (2023).
4. Seyed-Khorrami, S. M. et al. A promising future in cancer immunotherapy: Oncolytic viruses. Eur. J. Pharmacol. 3, 176063 (2023).
5. Xiao, B. et al. Oncolytic adenovirus CD55-Smad4 suppresses cell proliferation, metastasis, and tumor stemness in colorectal cancer by regulating Wnt/β-catenin signaling pathway. Biomedicines 8(12), 593 (2020).